Biotech Values

[jbog]

While Altimmune is in the basement, it's seeing a little upside because of it's GLP-1/Glucagon Dual Receptor components.

To all the Viking holders, I had Alt last year as it released data similar (no worse) than Viking and the stock went from $3 to $23 in no time. The market then took it right back to $3 over a couple of months. Alt did run a stupid trial that helped the decline.